v3.26.1
Operating Segment and Revenue Information (Tables)
 12 Months Ended
Mar. 31, 2026
Disclosure of operating segments [abstract]  
Schedule of Disaggregation of Revenue Information
Takeda’s revenue from contracts with customers is comprised of the following:
Revenue by Type of Good or Service
JPY (millions)
For the Year Ended March 31
202420252026
Sales of pharmaceutical products
¥4,163,652 ¥4,495,972 ¥4,423,111 
Out-licensing and service income
100,110 85,579 82,609 
Total
¥4,263,762 ¥4,581,551 ¥4,505,720 
Revenue by Business Area and Product
JPY (millions)
For the Year Ended March 31
202420252026
Gastroenterology:
ENTYVIO¥800,919 ¥914,098 ¥958,042 
GATTEX/REVESTIVE119,252 146,289 145,659 
TAKECAB/VOCINTI*
118,526 130,763 143,684 
DEXILANT45,278 38,548 37,259 
EOHILIA200 5,452 8,780 
RESOLOR/MOTEGRITY20,880 19,481 7,261 
Others111,153 102,391 106,776 
Total Gastroenterology 1,216,207 1,357,022 1,407,460 
Rare Diseases:
TAKHZYRO178,677 223,163 223,924 
ADVATE122,911 111,758 105,518 
ELAPRASE91,561 97,243 100,485 
REPLAGAL73,553 77,852 80,425 
ADYNOVATE/ADYNOVI66,308 64,613 56,689 
LIVTENCITY19,085 32,997 46,909 
VONVENDI16,188 20,934 25,282 
ADZYNMA425 7,082 11,957 
Others119,715 117,173 111,510 
Total Rare Diseases688,423 752,816 762,698 
PDT:
Immunoglobulin644,587 757,771 790,571 
Albumin133,990 141,381 140,316 
FEIBA40,543 39,431 32,868 
HEMOFIL/IMMUNATE/IMMUNINE19,518 25,586 25,377 
JPY (millions)
For the Year Ended March 31
202420252026
Others65,062 68,493 68,392 
Total PDT903,699 1,032,662 1,057,524 
Oncology:
ADCETRIS109,425 129,025 140,213 
LEUPLIN/ENANTONE107,350 119,265 120,789 
NINLARO87,361 91,242 82,109 
ICLUSIG54,706 70,728 75,045 
FRUZAQLA10,080 47,954 55,113 
ALUNBRIG28,524 36,432 36,934 
Others64,915 65,783 69,923 
Total Oncology462,362 560,430 580,126 
Vaccines:
QDENGA9,557 35,580 40,767
Others40,798 19,832 18,840 
Total Vaccines50,355 55,412 59,607 
Neuroscience:
VYVANSE/ELVANSE423,221 350,607 203,233 
TRINTELLIX104,797 125,735 121,841 
ADDERALL XR41,756 28,430 24,748 
Others57,241 61,044 64,521 
Total Neuroscience627,014 565,816 414,343 
Other:
FOSRENOL13,529 7,911 8,842 
AZILVA*
33,636 11,808 7,142 
Others268,536 237,673 207,977 
Total Other315,701 257,392 223,961 
Total¥4,263,762 ¥4,581,551 ¥4,505,720 
* The figures include the amounts of fixed dose combinations and blister packs.
Schedule of Geographic Information
Takeda’s revenue from contracts with customers is based in the following geographic locations:
JPY (millions)
For the Year Ended March 31
202420252026
Japan¥451,391 ¥418,462 ¥433,110 
U.S.2,195,711 2,379,651 2,164,824 
Europe and Canada966,835 1,055,252 1,146,238 
Latin America198,100 235,848 254,132 
China174,844 191,740 195,136 
Asia (excluding Japan & China)86,375 99,392 98,669 
Russia/CIS72,594 72,356 79,719 
Other117,911 128,849 133,892 
Total¥4,263,762 ¥4,581,551 ¥4,505,720 
Takeda’s non-current assets are held in the following geographic locations:
JPY (millions)
As of March 31
20252026
Japan
¥317,089 ¥281,337 
U.S.
7,654,971 7,717,157 
Switzerland
799,783 1,018,628 
Ireland872,944 987,923 
Other1,330,348 1,404,855 
Total¥10,975,135 ¥11,409,899 
Schedule of Contract Balances
Contract Balances
JPY (millions)
As of March 31
20252026
Receivables from contracts with customers
Trade receivables (Note 16)
¥651,414 ¥808,025 
Contract assets
Unbilled receivables
1,372 1,609 
Contract liabilities
Deferred income (Note 23)
23,547 11,575 
Advance payments
64 93 
Schedule of Transaction Price Allocated to the Remaining Performance Obligations
Transaction price allocated to the remaining performance obligations
JPY (millions)
Total
Duration of the remaining performance obligations
Within one year
Between one and five years
More than five years
Contract liabilities as of March 31, 2025
¥23,611 ¥21,781 ¥526 ¥1,304 
Contract liabilities as of March 31, 2026
11,668 7,094 2,812 1,762